DarioHealth (NASDAQ:DRIO) Price Target Raised to $18.00

DarioHealth (NASDAQ:DRIO – Get Rating) had its price target boosted by Cowen from $14.00 to $18.00 in a research note released on Monday, The Fly reports.

Several other equities analysts also recently issued reports on the stock. Alliance Global Partners raised shares of DarioHealth from a neutral rating to a buy rating and set a $8.75 price objective on the stock in a report on Friday, May 13th. Aegis decreased their price objective on shares of DarioHealth from $28.00 to $25.00 and set a buy rating on the stock in a report on Wednesday, January 26th. Finally, Cowen decreased their price objective on shares of DarioHealth from $30.00 to $14.00 in a report on Monday, April 18th. Three equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of Buy and a consensus price target of $17.44.

DRIO stock opened at $6.45 on Monday. The firm has a market cap of $141.82 million, a PE ratio of -1.61 and a beta of 1.36. The firm’s fifty day moving average is $5.82 and its 200 day moving average is $9.86. DarioHealth has a one year low of $4.11 and a one year high of $23.80.

DarioHealth (NASDAQ:DRIO – Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.22. DarioHealth had a negative net margin of 311.13% and a negative return on equity of 73.61%. During the same quarter last year, the firm earned ($0.92) EPS. Research analysts predict that DarioHealth will post -3.17 EPS for the current year.

Several large investors have recently bought and sold shares of DRIO. Steward Partners Investment Advisory LLC purchased a new position in shares of DarioHealth in the first quarter worth about $25,000. UBS Group AG lifted its stake in shares of DarioHealth by 706.5% in the third quarter. UBS Group AG now owns 4,250 shares of the company’s stock worth $58,000 after buying an additional 3,723 shares in the last quarter. Morgan Stanley lifted its stake in shares of DarioHealth by 219.2% in the first quarter. Morgan Stanley now owns 3,543 shares of the company’s stock worth $68,000 after buying an additional 2,433 shares in the last quarter. Focused Wealth Management Inc lifted its stake in shares of DarioHealth by 150,000.0% in the fourth quarter. Focused Wealth Management Inc now owns 6,004 shares of the company’s stock worth $78,000 after buying an additional 6,000 shares in the last quarter. Finally, Klingman & Associates LLC purchased a new position in DarioHealth during the first quarter worth about $86,000. 49.01% of the stock is currently owned by hedge funds and other institutional investors.

DarioHealth Company Profile (Get Rating)

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.

Recommended Stories